Background-Although previous work has suggested that anemia is associated with an increased mortality in selected patients with congestive heart failure (CHF), little is known about the prevalence and predictors of anemia, or whether anemia is an independent prognostic factor in unselected, community-based patients with CHF. 
D
espite remarkable advances in diagnosis and therapy over the past decade, the prognosis of patients with heart failure remains poor. Identification of factors that adversely affect quality of life or survival in heart failure may not only aid in better definition of prognosis but could also potentially provide new opportunities for novel therapeutic strategies in these patients.
Although anemia (and its correction) is a well-recognized comorbidity in a variety of conditions, including myocardial ischemia, its role in heart failure has only recently received attention. [1] [2] [3] [4] Two studies have examined the prevalence and prognosis of anemia in highly selected CHF populations; prevalence was 4% in clinical trial participants (nϭ6797) with asymptomatic or mild left ventricular dysfunction (relative risk [RR] for death was 1.03 [95% confidence interval (CI) 1.02 to 1.04] for each 1% drop in hematocrit in this sample), 1 whereas 30% of patients (nϭ1061) followed-up in a specialized clinic for advanced heart failure had anemia (RR 1.13 [95% CI 1.05 to 1.22] for mortality). 2 In a small population-based cohort (nϭ633) of Medicare beneficiaries admitted to hospital for CHF, 14% had an admission hematocrit Ͻ30%, and these anemic patients had increased mortality at 1 year (RR 1.60 [95% CI 1.19 to 2.16]) compared with those with a hematocrit Ն40%. 3 Little is known about the prevalence or prognostic importance of anemia in a large unselected population of patients with heart failure.
Methods
We examined a population-based cohort of 12 065 patients with new-onset heart failure in Alberta, Canada (total population 3.06 million). We used hospital discharge data to identify all patients hospitalized at least once for a most responsible diagnosis of heart failure (International Classification of Diseases [ICD]-9 code 428.x) between April 1993 and March 2001, and collated their comorbidities. The accuracy of our data acquisition and the use of discharge coding to identify cases and comorbidities have been described elsewhere. 5, 6 To establish a cohort of incident cases, we excluded patients hospitalized for heart failure in the 12 months preceding the index hospitalization, as well as those who died during the index hospitalization.
We linked the study sample to the Alberta Health Care Insurance Registry, which tracks the vital status of all individuals in the province, and followed-up with all patients from the date of their index hospitalization until the date of their death or September 30, 2001, whichever came first. We determined the prevalence of anemia at the time of initial diagnosis of heart failure (using ICD-9 codes 280 to 289 to capture "all anemia" and 285.9 to capture "anemia of chronic disease") and examined for differences between patients who did and did not have anemia at baseline (Table) . Continuous variables were compared using ANOVA adjusted for multiple comparisons by Tukey's test, and ordinal and dichotomous variables were compared using the 2 test. Mortality rates of patients who were anemic when heart failure was diagnosed and those without anemia were compared using the Cox proportional hazards model, controlling for comorbidities and the known prognostic factors in heart failure (listed in the Table) . Data for regression analysis is presented as odds or hazard ratio with 95% confidence intervals. In a sensitivity analysis to minimize confounding by unmeasured comorbidities, we examined the associations between anemia and outcomes in the youngest and healthiest subgroup (patients Ͻ65 years without documented comorbidities).
Results
The median age of our 12 065 patients was 78 years; 17% had anemia (21% iron deficiency, 8% other deficiency, 13% assorted other identifiable causes, and 58% had anemia of chronic disease). Baseline features are outlined in the Median follow-up was 573 days (interquartile range 155 to 1224 days), and the 1-year and 5-year mortality rates were 38% and 59% in those with anemia, respectively, compared with 27% and 50% for those without anemia. The survival of patients with anemia was worse even after adjustment for the known prognostic factors and comorbidities in the Table (Figure) . Cox proportional hazard ratios for mortality were 1.34 (1.24 to 1.46) in anemic patients, and 1.36 (1.23 to 1.50) in the subset of patients with anemia of chronic disease. As a sensitivity analysis, we restricted this analysis to the youngest and healthiest subgroup (nϭ654) and found that anemia was even more strongly associated with mortality (OR 2.4 [1.2 to 4.6]).
Discussion
The key novel findings of our study are the demonstration among a large population-based cohort of CHF patients that anemia is common, that it is an independent prognostic factor, and that the majority of heart failure patients with anemia have anemia of chronic disease. There are several possible explanations for our findings. First, reduced hemoglobin may merely be a marker for the epiphenomena of advanced heart failure (such as hemodilution due to volume overload, malnutrition from cardiac cachexia, or renal insufficiency). An earlier study in patients with New York Heart Association class III or IV failure demonstrated, however, that hemoglobin was an important prognostic factor independent of the pulmonary capillary wedge pressure, body mass index, serum albumin, or serum creatinine. 2 Furthermore, anemia was an independent predictor of mortality independent of serum creatinine in 2 previous studies. 1, 3 Second, because angiotensin-converting enzyme (ACE) inhibitors may inhibit hematopoietic cell proliferation, it is possible that anemia may be a marker for patients receiving higher doses of ACE inhibitors. 7, 8 This seems unlikely, however, as the presence of anemia seems to be independent of ACE inhibitor use (and dosing). 1,2 Third, although anemia may predispose at-risk patients to myocardial ischemia, the prognostic impact of anemia was independent of a diagnosis of ischemic heart disease in our data. Finally, inflammation, characterized by increases in cytokines such as tumor necrosis factor-␣, 9 is now thought to be a pathophysiological modulator of heart failure. Hence, we believe it is reasonable to hypothesize that heart failure may cause anemia of chronic disease through cytokine-mediated bone marrow suppression. 7 As this is an observational study, some potential limitations deserve discussion. Values are presented as meanϮSD or n (%). Note that the 1208 patients classified as having anemia of chronic disease represent a subset of the 2083 patients with any anemia. COPD indicates chronic obstructive pulmonary disease.
* PϽ0.005 for comparison with no anemia. Statistical significance adjusted for multiple comparisons using the Bonferroni correction.
Survival of heart failure patients with and without anemia at the time of initial diagnosis of heart failure. These survival curves were generated using Kaplan-Meier methods (PϽ0.0001 for anemia present versus anemia absent). For results of Cox proportional hazards modeling, please see text.
bases are well known and described elsewhere. 5 However, previous studies have confirmed the accuracy of our data sources and coding for heart failure. 5, 6 Further, all of our analyses were adjusted for known prognostic factors in heart failure, and we confirmed the robustness of our findings in a sensitivity analysis in the youngest and healthiest subgroup, where unmeasured confounding would presumably be minimized. 10 We believe efforts to better detect anemia in heart failure patients, discern the pathophysiology of, and test new therapies for anemia in heart failure should be a future priority.
Indeed, small open-label studies have shown improvements in functional capacity and ejection fraction with correction of anemia using erythropoietin with intravenous iron. 4, 11 There is clearly a need for an appropriately powered randomized trial with meaningful clinical endpoints, such as hospitalizations and mortality, to evaluate the impact of such therapies in anemic heart failure patients.
